Shree Ganesh Remedies Ltd

Shree Ganesh Remedies Ltd — Trading Window Closure from Oct 01, 2026 till 48 hours after declaration of Unaudited Financial Results for quarter and half year ended September 30, 2026

AGM Details

• AGM held on 12 September 2026 via VC/OVM.
• Record date 5 September 2026; outstanding shares 12,837,620.

Key Resolutions

• Ordinary: Adopt standalone and consolidated financial statements.
• Ordinary: Reappoint Chandulal Manubhai Kothia by rotation.
• Ordinary: Ratify remuneration to Cost Auditors for FY2027.
• Special: Appoint Ankitkumar Shah as Independent Director.

Voting Outcomes

• Resolution 1 passed; majority in favour.
• Resolution 2 passed; majority in favour.
• Resolution 3 passed; 2 votes against.
• Resolution 4 results not disclosed in this excerpt.

Appointments & Changes

• Chandulal Kothia reappointed by rotation.
• Ankitkumar Shah appointed as Independent Director.

AGM Details

• Date and time: September 12, 2026, 11:30 a.m. to 11:58 a.m.
• Mode: VC/OAVM.
• Electronic voting window: Sep 9–11, 2026.

Ordinary Business

• Adopt audited standalone and consolidated financial statements for FY ended March 31, 2026.
• Re-appoint director retiring by rotation: Chandulal Manubhai Kothia.

Special Business

• Ratify remuneration payable to cost auditors for year ending March 31, 2027.
• Approve appointment of Ms. Hiral Ankitkumar Shah as Independent Director.

Voting & Results Status

• Scrutinizer appointed to conduct e-voting.
• Detailed voting results to be submitted separately.

Financial highlights

• FY26 revenue ₹10,928.58 Lakhs; broadly flat vs FY25.
• EBITDA ₹3,502 Lakhs; margin 32.0%.
• PAT ₹1,777.33 Lakhs.
• Net debt near debt-free; balance sheet robust.
• Q4 momentum improved; shipments recovered.

Operations & capacity

• Block 7 expansion on track; commercial production due FY27 Q3.
• New pilot facility fully operational; enables flow chemistry.
• Block 8 capex completed FY25; ramping up.
• CRAMS molecules moving to commercial trials; awaiting approvals.
• Capacity utilisation 60-70%; peak 80-85% in blocks.

Growth & strategy

• Shift up the value chain; specialty and CRAMS driving growth.
• Pharma intermediates ~62% of FY26 revenue; CRAMS growing.
• Exports dominate; footprint across 20+ countries.

Capex & projects

• FY26 capex ₹15 Crore on new block and R&D.
• Block 7 commissioning expected FY27; Dahej infra progressing.
• Pilot facility with automation and flow chemistry commissioned FY26.
• Block 8 completed FY25; ramping up.

Governance & risk

• Board of 5; Shruti Sohane appointed Aug 2025; Priyam Shah resigned.
• Hiral Shah appointed Additional Independent Director July 2026.
• Auditors Chaudhary Shah & Associates; clean report.
• Internal controls robust; risk management in place.
• Risks: Europe slowdown, commodity price volatility, regulatory delays.

CSR & ESG

• CSR spend ₹60.30 Lakhs; 2% average net profit ₹59.79 Lakhs.
• CSR focuses on Education, Animal Welfare, Environment.
• 5 MW solar park; up to 70% electricity from renewables.
• In-house effluent treatment and waste management.

Outlook & AGM

• FY27 outlook: groundwork to translate into growth; pipeline strengthening.
• 31st AGM Sep 12, 2026 via VC/OAVM.
• Dividend: no dividend declared for FY26.

Overview & Strategy

• Pharma intermediates and specialty chemicals; complex chemistry capabilities.
• Shifting toward patented molecules; Ankleshwar expansion and Dahej land acquisition.
• Collaborations with industry leaders; expanding R&D and pilot infrastructure.

Q1FY27 Financials

• Revenue from Operations ₹14.36 cr; YoY down 42%.
• Total Income ₹15.30 cr; YoY down 40%.
• EBITDA (Excl OI & EI) ₹3.35 cr; margin 23.3%.
• PAT ₹1.12 cr; YoY down 68%.

Balance Sheet & Cash Flow

• Shareholders' Funds ₹163.02 cr (FY26).
• Total Assets ₹207.74 cr (FY26).
• Net Cash Flow ₹2.17 cr; FY26 positive.
• Cash & Bank Balances ₹13.45 cr (FY26).

Capex, Infrastructure & Growth

• Block 7 commissioning planned H1FY27; CAPEX ~₹20 cr.
• Plant 8 completed in FY25; FY26 CAPEX ₹15 cr for expansion & R&D.
• Dahej expansion planned; land acquired 40,554 sq m for ₹11 cr.
• R&D facilities: DSIR-recognized; pilot plant expansion underway.

Risks & Outlook

• Geopolitical headwinds and EU demand softness; volumes expected to recover H2FY27.
• Transition from distributor to direct customer relationships to regain volumes.

Financial Highlights

• Q1FY27 revenue from operations ₹14.36 crore; YoY decline 42%.
• Total income ₹15.30 crore; YoY decline 40%.
• EBITDA ₹3.35 crore; EBITDA margin 23.3%.
• PAT ₹1.12 crore; EPS ₹0.87.

Operational & Strategic Updates

• EU distributor agreement terminated for non-performance; company to engage directly with customers.
• CRAMS in South-East Asia progressing; revenue contribution expected in H2FY27.
• FY27 guidance moderated; second half expected to show meaningful improvement as catalysts come online.
• Block 7 commissioning on course; strategic direction unchanged.

Financial results

• Unaudited standalone and consolidated results for quarter ended June 30, 2026 approved; Limited Review Reports enclosed.

Cost auditors appointed

• Appointed M/s. M. I. Prajapati & Associates LLP as Cost Auditors for 2026-27, effective Aug 12, 2026.

AGM Scrutinizer

• Appointed Vishal Thawani (M/s VTSN & Associates LLP) as Scrutinizer for e-voting at 31st AGM.

AGM notice and Directors Report

• Notice for 31st AGM and Directors Report with annexures for year ended March 31, 2026.

Regulatory disclosures

• Annexure A provides Regulation 30 SEBI LODR disclosures; Master Circular dated Jan 30, 2026.

Meeting Details

• Board meeting scheduled for August 12, 2026; time and venue not disclosed.

Key Agenda Items

• Consider unaudited standalone and consolidated financial results for quarter ended June 30, 2026.

Other Notes

• Trading window closed from July 1, 2026 until 48 hours after the results are made public.